Aleksic S, Eisenberg R, Tsomos E, et al. - Since there exists little knowledge regarding glycemic management, especially with new cardio-nephroprotecive agents, among underserved minority kidney transplant recipients having pre-transplant type 2 (T2DM) and posttransplantation diabetes mellitus (PTDM), therefore, researchers evaluated glycemic management as well as outcomes in this high-risk group. For patients who underwent kidney transplantation between June 2012 and December 2014 at a single center, data were analyzed. After transplantation, 302 patient records (41.1% Hispanic, 41.1% non-Hispanic black) were studied for a median of 45.5 months. The presence of pre-transplant T2DM was noted in 152 (50.3%), while PTDM was detected in 58 (19.2%) and 92 (30.4%) remained without diabetes. In T2DM and in PTDM, the average hemoglobin A1c (HbA1c) was identified to be 8.1±1.8% and 6.6±1.3%, respectively, at 1-year after transplantation. In T2DM and in PTDM, no glucose-lowering agents were prescribed in 3.4% and 44.8%, respectively. When treated, both took mostly insulin and metformin. There was no independent link of diabetes, HbA1c and insulin therapy, with the risk of death. Overall, suboptimal glycemic management was reported and glycemic management depended on older medications.